• +91 9169164321 (Asia)
  • +1(646)-781-7170 (Int'l)
  • help@24lifesciences.com
Cart (0)

COVID-19 Impact on NASH (Non-alcoholic Steatohepatitis) Biomarkers Market, Global Research Reports 2020-2021

report cover
  • 20 May 2020
  • Medical Devices
  • 96 Pages
  • Report Code: 24LS-2798
  • Formate :   
Download FREE Report Sample Download PDF File

COVID 19 Impact NASH Biomarkers Market Reports -MARKET ADVISORY SERVICES

This report covers market size and forecasts of NASH (Non-alcoholic Steatohepatitis) Biomarkers, including the following market information:

  • Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Market Size, 2019-2021, and 2020 (quarterly data), (US$ Million) & (K Units)
  • Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Market Size by Type and by Application, 2019-2021, and 2020 (quarterly data), (US$ Million) & (K Units)
  • Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Market Size by Region (and Key Countries), 2019-2021, and 2020 (quarterly data), (US$ Million) & (K Units)
  • Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Market Size by Company, 2019- 2020 (quarterly data), (US$ Million) & (K Units)


Key market players
Major competitors identified in this market include GENFIT SA, Gilead Sciences, Inc. (GILD), AstraZeneca, Novartis AG, Bristol-Myers Squibb Company, Allergan Plc, Novo Nordisk A/S, Boehringer Ingelheim, Pfizer Inc, etc.

Based on the Region:

  • Asia-Pacific (China, Japan, South Korea, India and ASEAN)
  • North America (US and Canada)
  • Europe (Germany, France, UK and Italy)
  • Rest of World (Latin America, Middle East & Africa)


Based on the Type:

  • Serum biomarkers
  • Hepatic fibrosis biomarkers
  • Apoptosis biomarkers
  • Oxidative stress biomarkers
  • Others


Based on the Application:

  • Pharma & CRO Industry
  • Hospitals
  • Diagnostic Labs
  • Academic Research Institutes
1.1 Research Scope
1.2 Market Segmentation
1.3 Research Objectives
1.4 Research Methodology
1.4.1 Research Process
1.4.2 Data Triangulation
1.4.3 Research Approach
1.4.4 Base Year
1.5 Coronavirus Disease 2019 (Covid-19) Impact Will Have a Severe Impact on Global Growth
1.5.1 Covid-19 Impact: Global GDP Growth, 2019, 2020 and 2021 Projections
1.5.2 Covid-19 Impact: Commodity Prices Indices
1.5.3 Covid-19 Impact: Global Major Government Policy
1.6 The Covid-19 Impact on NASH (Non-alcoholic Steatohepatitis) Biomarkers Industry
1.7 COVID-19 Impact: NASH (Non-alcoholic Steatohepatitis) Biomarkers Market Trends

2 Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Quarterly Market Size Analysis
2.1 NASH (Non-alcoholic Steatohepatitis) Biomarkers Business Impact Assessment - COVID-19
2.1.1 Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Market Size, Pre-COVID-19 and Post- COVID-19 Comparison, 2015-2026
2.1.2 Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Price, Pre-COVID-19 and Post- COVID-19 Comparison, 2015-2026
2.2 Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Quarterly Market Size 2020-2021
2.3 COVID-19-Driven Market Dynamics and Factor Analysis
2.3.1 Drivers
2.3.2 Restraints
2.3.3 Opportunities
2.3.4 Challenges

3 Quarterly Competitive Assessment, 2020
3.1 Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Quarterly Market Size by Manufacturers, 2019 VS 2020
3.2 Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Factory Price by Manufacturers
3.3 Location of Key Manufacturers NASH (Non-alcoholic Steatohepatitis) Biomarkers Manufacturing Factories and Area Served
3.4 Date of Key Manufacturers Enter into NASH (Non-alcoholic Steatohepatitis) Biomarkers Market
3.5 Key Manufacturers NASH (Non-alcoholic Steatohepatitis) Biomarkers Product Offered
3.6 Mergers & Acquisitions, Expansion Plans

4 Impact of Covid-19 on NASH (Non-alcoholic Steatohepatitis) Biomarkers Segments, By Type
4.1 Introduction
1.4.1 Serum biomarkers
1.4.2 Hepatic fibrosis biomarkers
1.4.3 Apoptosis biomarkers
1.4.4 Oxidative stress biomarkers
1.4.5 Others
4.2 By Type, Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Market Size, 2019-2021
4.2.1 By Type, Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Market Size by Type, 2020-2021
4.2.2 By Type, Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Price, 2020-2021

5 Impact of Covid-19 on NASH (Non-alcoholic Steatohepatitis) Biomarkers Segments, By Application
5.1 Overview
5.5.1 Pharma & CRO Industry
5.5.2 Hospitals
5.5.3 Diagnostic Labs
5.5.4 Academic Research Institutes
5.2 By Application, Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Market Size, 2019-2021
5.2.1 By Application, Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Market Size by Application, 2019-2021
5.2.2 By Application, Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Price, 2020-2021

6 Geographic Analysis
6.1 Introduction
6.2 North America
6.2.1 Macroeconomic Indicators of US
6.2.2 US
6.2.3 Canada
6.3 Europe
6.3.1 Macroeconomic Indicators of Europe
6.3.2 Germany
6.3.3 France
6.3.4 UK
6.3.5 Italy
6.4 Asia-Pacific
6.4.1 Macroeconomic Indicators of Asia-Pacific
6.4.2 China
6.4.3 Japan
6.4.4 South Korea
6.4.5 India
6.4.6 ASEAN
6.5 Rest of World
6.5.1 Latin America
6.5.2 Middle East and Africa

7 Company Profiles
7.1 GENFIT SA
7.1.1 GENFIT SA Business Overview
7.1.2 GENFIT SA NASH (Non-alcoholic Steatohepatitis) Biomarkers Quarterly Production and Revenue, 2020
7.1.3 GENFIT SA NASH (Non-alcoholic Steatohepatitis) Biomarkers Product Introduction
7.1.4 GENFIT SA Response to COVID-19 and Related Developments
7.2 Gilead Sciences, Inc. (GILD)
7.2.1 Gilead Sciences, Inc. (GILD) Business Overview
7.2.2 Gilead Sciences, Inc. (GILD) NASH (Non-alcoholic Steatohepatitis) Biomarkers Quarterly Production and Revenue, 2020
7.2.3 Gilead Sciences, Inc. (GILD) NASH (Non-alcoholic Steatohepatitis) Biomarkers Product Introduction
7.2.4 Gilead Sciences, Inc. (GILD) Response to COVID-19 and Related Developments
7.3 AstraZeneca
7.3.1 AstraZeneca Business Overview
7.3.2 AstraZeneca NASH (Non-alcoholic Steatohepatitis) Biomarkers Quarterly Production and Revenue, 2020
7.3.3 AstraZeneca NASH (Non-alcoholic Steatohepatitis) Biomarkers Product Introduction
7.3.4 AstraZeneca Response to COVID-19 and Related Developments
7.4 Novartis AG
7.4.1 Novartis AG Business Overview
7.4.2 Novartis AG NASH (Non-alcoholic Steatohepatitis) Biomarkers Quarterly Production and Revenue, 2020
7.4.3 Novartis AG NASH (Non-alcoholic Steatohepatitis) Biomarkers Product Introduction
7.4.4 Novartis AG Response to COVID-19 and Related Developments
7.5 Bristol-Myers Squibb Company
7.5.1 Bristol-Myers Squibb Company Business Overview
7.5.2 Bristol-Myers Squibb Company NASH (Non-alcoholic Steatohepatitis) Biomarkers Quarterly Production and Revenue, 2020
7.5.3 Bristol-Myers Squibb Company NASH (Non-alcoholic Steatohepatitis) Biomarkers Product Introduction
7.5.4 Bristol-Myers Squibb Company Response to COVID-19 and Related Developments
7.6 Allergan Plc
7.6.1 Allergan Plc Business Overview
7.6.2 Allergan Plc NASH (Non-alcoholic Steatohepatitis) Biomarkers Quarterly Production and Revenue, 2020
7.6.3 Allergan Plc NASH (Non-alcoholic Steatohepatitis) Biomarkers Product Introduction
7.6.4 Allergan Plc Response to COVID-19 and Related Developments
7.7 Novo Nordisk A/S
7.7.1 Novo Nordisk A/S Business Overview
7.7.2 Novo Nordisk A/S NASH (Non-alcoholic Steatohepatitis) Biomarkers Quarterly Production and Revenue, 2020
7.7.3 Novo Nordisk A/S NASH (Non-alcoholic Steatohepatitis) Biomarkers Product Introduction
7.7.4 Novo Nordisk A/S Response to COVID-19 and Related Developments
7.8 Boehringer Ingelheim
7.8.1 Boehringer Ingelheim Business Overview
7.8.2 Boehringer Ingelheim NASH (Non-alcoholic Steatohepatitis) Biomarkers Quarterly Production and Revenue, 2020
7.8.3 Boehringer Ingelheim NASH (Non-alcoholic Steatohepatitis) Biomarkers Product Introduction
7.8.4 Boehringer Ingelheim Response to COVID-19 and Related Developments
7.9 Pfizer Inc
7.9.1 Pfizer Inc Business Overview
7.9.2 Pfizer Inc NASH (Non-alcoholic Steatohepatitis) Biomarkers Quarterly Production and Revenue, 2020
7.9.3 Pfizer Inc NASH (Non-alcoholic Steatohepatitis) Biomarkers Product Introduction
7.9.4 Pfizer Inc Response to COVID-19 and Related Developments

8 Supply Chain and Sales Channels Analysis
8.1 NASH (Non-alcoholic Steatohepatitis) Biomarkers Supply Chain Analysis
8.1.1 NASH (Non-alcoholic Steatohepatitis) Biomarkers Supply Chain Analysis
8.1.2 Covid-19 Impact on NASH (Non-alcoholic Steatohepatitis) Biomarkers Supply Chain
8.2 Distribution Channels Analysis
8.2.1 NASH (Non-alcoholic Steatohepatitis) Biomarkers Distribution Channels
8.2.2 Covid-19 Impact on NASH (Non-alcoholic Steatohepatitis) Biomarkers Distribution Channels
8.2.3 NASH (Non-alcoholic Steatohepatitis) Biomarkers Distributors
8.3 NASH (Non-alcoholic Steatohepatitis) Biomarkers Customers

9 Key Findings

10 Appendix
10.1 About Us
10.2 Disclaimer
List of Tables

Table 1. Overview of the World Economic Outlook Projections

Table 2. Summary of World Real per Capita Output (Annual percent change; in international currency at purchasing power parity)

Table 3. European Economies: Real GDP, Consumer Prices, Current Account Balance, and Unemployment (Annual percent change, unless noted otherwise)

Table 4. Asian and Pacific Economies: Real GDP, Consumer Prices, Current Account Balance, and Unemployment (Annual percent change, unless noted otherwise)

Table 5. Western Hemisphere Economies: Real GDP, Consumer Prices, Current Account Balance, and Unemployment (Annual percent change, unless noted otherwise)

Table 6. Middle Eastern and Central Asian Economies: Real GDP, Consumer Prices, Current Account Balance, and Unemployment (Annual percent change, unless noted otherwise)

Table 7. Covid-19 Impact: Global Major Government Policy

Table 8. The Covid-19 Impact on NASH (Non-alcoholic Steatohepatitis) Biomarkers Assessment

Table 9. COVID-19 Impact: NASH (Non-alcoholic Steatohepatitis) Biomarkers Market Trends

Table 10. COVID-19 Impact Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Market Size

Table 11. Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Market Size Pre-COVID-19 and Post- COVID-19 Comparison, 2015-2026 (K Units)

Table 12. Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Price, Pre-COVID-19 and Post- COVID-19 Comparison, 2015-2026, (USD/Unit)

Table 13. Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Quarterly Market Size, 2020 (US$ Million) & (K Units)

Table 14. Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Market Size, Pre-COVID-19 and Post- COVID-19 Quarterly Comparison, 2020-2021 (US$ Million)

Table 15. Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Market Size, Pre-COVID-19 and Post- COVID-19 Quarterly Comparison, 2020-2021 (K Units)

Table 16. Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Market Growth Drivers

Table 17. Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Market Restraints

Table 18. Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Market Opportunities

Table 19. Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Market Challenges

Table 20. Key Manufacturers NASH (Non-alcoholic Steatohepatitis) Biomarkers Quarterly Revenue, 2019 VS 2020 (US$ Million)

Table 21. Top Manufacturers, NASH (Non-alcoholic Steatohepatitis) Biomarkers Market Size, 2019 (K Units) & (US$ Million)

Table 22. NASH (Non-alcoholic Steatohepatitis) Biomarkers Factory Price by Manufacturers 2020 (USD/Unit)

Table 23. Location of Key Manufacturers NASH (Non-alcoholic Steatohepatitis) Biomarkers Manufacturing Plants

Table 24. Key Manufacturers NASH (Non-alcoholic Steatohepatitis) Biomarkers Market Served

Table 25. Date of Key Manufacturers Enter into NASH (Non-alcoholic Steatohepatitis) Biomarkers Market

Table 26. Key Manufacturers NASH (Non-alcoholic Steatohepatitis) Biomarkers Product Type

Table 27. Mergers & Acquisitions, Expansion Plans

Table 28. Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Market Size by Type, 2020, (US$ Million)

Table 29. Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Market Size by Type, 2020 (K Units)

Table 30. Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Price: by Type, 2020-2021 (USD/Unit)

Table 31. Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Market Size by Application: 2020-2021 (US$ Million)

Table 32. Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Market Size by Application, 2020-2021 (K Units)

Table 33. Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Price: by Application, 2020-2021 (USD/Unit)

Table 34. Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Market Size by Region, 2019-2021 (US$ Million)

Table 35. Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Market Size by Region, 2019-2021 (K Units)

Table 36. By Country, North America NASH (Non-alcoholic Steatohepatitis) Biomarkers Market Size, 2019-2021 (US$ Million)

Table 37. By Country, North America NASH (Non-alcoholic Steatohepatitis) Biomarkers Market Size, 2019-2021 (K Units)

Table 38. US NASH (Non-alcoholic Steatohepatitis) Biomarkers Market Size, 2019-2021 (US$ Million) & (K Units)

Table 39. Canada NASH (Non-alcoholic Steatohepatitis) Biomarkers Market Size, 2019-2021 (US$ Million) & (K Units)

Table 40. Macroeconomic Indicators of Europe (Germany, France, UK and Italy)

Table 41. By Country, Europe NASH (Non-alcoholic Steatohepatitis) Biomarkers Market Size, 2019-2021 (US$ Million)

Table 42. By Country, Europe NASH (Non-alcoholic Steatohepatitis) Biomarkers Market Size, 2019-2021 (K Units)

Table 43. Germany NASH (Non-alcoholic Steatohepatitis) Biomarkers Market Size, 2019-2021 (US$ Million) & (K Units)

Table 44. France NASH (Non-alcoholic Steatohepatitis) Biomarkers Market Size, 2019-2021 (US$ Million) & (K Units)

Table 45. UK NASH (Non-alcoholic Steatohepatitis) Biomarkers Market Size, 2019-2021 (US$ Million) & (K Units)

Table 46. Italy NASH (Non-alcoholic Steatohepatitis) Biomarkers Market Size, 2019-2021 (US$ Million) & (K Units)

Table 47. Macroeconomic Indicators of Asia-Pacific (China, Japan, South Korea, India and ASEAN)

Table 48. By Region, Asia-Pacific NASH (Non-alcoholic Steatohepatitis) Biomarkers Market Size, 2019-2021 (US$ Million)

Table 49. By Region, Asia-Pacific NASH (Non-alcoholic Steatohepatitis) Biomarkers Market Size, 2019-2021 (K Units)

Table 50. China NASH (Non-alcoholic Steatohepatitis) Biomarkers Market Size, 2019-2021 (US$ Million) & (K Units)

Table 51. Japan NASH (Non-alcoholic Steatohepatitis) Biomarkers Market Size, 2019-2021 (US$ Million) & (K Units)

Table 52. South Korea NASH (Non-alcoholic Steatohepatitis) Biomarkers Market Size, 2019-2021 (US$ Million) & (K Units)

Table 53. India NASH (Non-alcoholic Steatohepatitis) Biomarkers Market Size, 2019-2021 (US$ Million) & (K Units)

Table 54. ASEAN NASH (Non-alcoholic Steatohepatitis) Biomarkers Market Size, 2019-2021 (US$ Million) & (K Units)

Table 55. Latin America NASH (Non-alcoholic Steatohepatitis) Biomarkers Market Size, 2019-2021 (US$ Million) & (K Units)

Table 56. Middle East and Africa NASH (Non-alcoholic Steatohepatitis) Biomarkers Market Size, 2019-2021 (US$ Million) & (K Units)

Table 57. GENFIT SA Business Overview

Table 58. GENFIT SA NASH (Non-alcoholic Steatohepatitis) Biomarkers Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin, (Q1, Q2, Q3, Q4) Quarter 2020

Table 59. GENFIT SA NASH (Non-alcoholic Steatohepatitis) Biomarkers Product

Table 60. GENFIT SA Response to COVID-19 and Related Developments

Table 61. Gilead Sciences, Inc. (GILD) Business Overview

Table 62. Gilead Sciences, Inc. (GILD) NASH (Non-alcoholic Steatohepatitis) Biomarkers Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin, (Q1, Q2, Q3, Q4) Quarter 2020

Table 63. Gilead Sciences, Inc. (GILD) NASH (Non-alcoholic Steatohepatitis) Biomarkers Product

Table 64. Gilead Sciences, Inc. (GILD) Response to COVID-19 and Related Developments

Table 65. AstraZeneca Business Overview

Table 66. AstraZeneca NASH (Non-alcoholic Steatohepatitis) Biomarkers Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin, (Q1, Q2, Q3, Q4) Quarter 2020

Table 67. AstraZeneca NASH (Non-alcoholic Steatohepatitis) Biomarkers Product

Table 68. AstraZeneca Response to COVID-19 and Related Developments

Table 69. Novartis AG Business Overview

Table 70. Novartis AG NASH (Non-alcoholic Steatohepatitis) Biomarkers Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin, (Q1, Q2, Q3, Q4) Quarter 2020

Table 71. Novartis AG NASH (Non-alcoholic Steatohepatitis) Biomarkers Product

Table 72. Novartis AG Response to COVID-19 and Related Developments

Table 73. Bristol-Myers Squibb Company Business Overview

Table 74. Bristol-Myers Squibb Company NASH (Non-alcoholic Steatohepatitis) Biomarkers Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin, (Q1, Q2, Q3, Q4) Quarter 2020

Table 75. Bristol-Myers Squibb Company NASH (Non-alcoholic Steatohepatitis) Biomarkers Product

Table 76. Bristol-Myers Squibb Company Response to COVID-19 and Related Developments

Table 77. Allergan Plc Business Overview

Table 78. Allergan Plc NASH (Non-alcoholic Steatohepatitis) Biomarkers Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin, (Q1, Q2, Q3, Q4) Quarter 2020

Table 79. Allergan Plc NASH (Non-alcoholic Steatohepatitis) Biomarkers Product

Table 80. Allergan Plc Response to COVID-19 and Related Developments

Table 81. Novo Nordisk A/S Business Overview

Table 82. Novo Nordisk A/S NASH (Non-alcoholic Steatohepatitis) Biomarkers Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin, (Q1, Q2, Q3, Q4) Quarter 2020

Table 83. Novo Nordisk A/S NASH (Non-alcoholic Steatohepatitis) Biomarkers Product

Table 84. Novo Nordisk A/S Response to COVID-19 and Related Developments

Table 85. Boehringer Ingelheim Business Overview

Table 86. Boehringer Ingelheim NASH (Non-alcoholic Steatohepatitis) Biomarkers Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin, (Q1, Q2, Q3, Q4) Quarter 2020

Table 87. Boehringer Ingelheim NASH (Non-alcoholic Steatohepatitis) Biomarkers Product

Table 88. Boehringer Ingelheim Response to COVID-19 and Related Developments

Table 89. Pfizer Inc Business Overview

Table 90. Pfizer Inc NASH (Non-alcoholic Steatohepatitis) Biomarkers Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin, (Q1, Q2, Q3, Q4) Quarter 2020

Table 91. Pfizer Inc NASH (Non-alcoholic Steatohepatitis) Biomarkers Product

Table 92. Pfizer Inc Response to COVID-19 and Related Developments

Table 93. NASH (Non-alcoholic Steatohepatitis) Biomarkers Distributors List

Table 94. NASH (Non-alcoholic Steatohepatitis) Biomarkers Customers List

Table 95. Covid-19 Impact on NASH (Non-alcoholic Steatohepatitis) Biomarkers Customers

List of Figures

Figure 1. NASH (Non-alcoholic Steatohepatitis) Biomarkers Product Picture

Figure 2. NASH (Non-alcoholic Steatohepatitis) Biomarkers Market Segmentation

Figure 3. Research Objectives

Figure 4. Research Process

Figure 5. Data Triangulation

Figure 6. Research Approach

Figure 7. Commodity Prices-Metals Price Indices

Figure 8. Commodity Prices- Precious Metal Price Indices

Figure 9. Commodity Prices- Agricultural Raw Material Price Indices

Figure 10. Commodity Prices- Food and Beverage Price Indices

Figure 11. Commodity Prices- Fertilizer Price Indices

Figure 12. Commodity Prices- Energy Price Indices

Figure 13. G20+: Economic Policy Responses to COVID-19

Figure 14. Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Market Size, Pre-COVID-19 and Post- COVID-19 Comparison, 2015-2026 (US$ Million)

Figure 15. Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Market Size, Pre-COVID-19 and Post- COVID-19, Year-over-Year Growth Rate, 2015-2026 (%)

Figure 16. Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Market Size, Quarterly Growth, 2020-2021 (%)

Figure 17. Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Market Size, Market Share by Type, 2019 VS 2020 (%)

Figure 18. Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Market Size, Market Share by Application, 2019 VS 2020 (%)

Figure 19. Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Market Size Market Share by Region, 2019 VS 2020 (%)

Figure 20. United States Composite PMI and GDP

Figure 21. Eurozone Composite PMI and GDP

Figure 22. Eurozone Core v. Periphery PMI Output Indices

Figure 23. Core v. Periphery PMI Employment Indices

Figure 24. UK Composite PMI and GDP

Figure 25. Caixin China Composite Output Index

Figure 26. Caixin China General Services Business Activity Index

Figure 27. Japan Composite Output Index

Figure 28. South Korea Manufacturing PMI

Figure 29. India Composite Output Index

Figure 30. ASEAN Manufacturing PMI

Figure 31. By Region, Asia-Pacific NASH (Non-alcoholic Steatohepatitis) Biomarkers Market Size Market Share, 2019-2021

GENFIT SA

Gilead Sciences, Inc. (GILD)

AstraZeneca

Novartis AG

Bristol-Myers Squibb Company

Allergan Plc

Novo Nordisk A/S

Boehringer Ingelheim

Pfizer Inc

CHOOSE YOUR BUYING OPTION COVID-19 Revised Pricing Of the Month

SECURITY ASSUREDpayment image

Frequently Asked Questions ?

  • A license granted to one user.

    A license granted to one user. Rules or conditions might be applied for e.g. the use of electric files (PDFs) or printings, depending on product.

  • Multi user License

    A license granted to multiple users.

  • Site License

    A license granted to a single business site/establishment.

  • Corporate License, Global License

    A license granted to all employees within organisation access to the product.

  • Upto Working 24 to 48 hrs

  • Upto 72 hrs max - Weekends and Public Holidays

  • Online Payments with PayPal and CCavenue

  • Wire Transfer/Bank Transfer

  • Email

  • Hard Copy

CHECK TODAYS BEST PRICE

BEST PRICE: $2665

SOME OF OUR CLIENTS

OUR KEY POINTS

  • Comprehensive Research

    Offers Penetrative insights & holistic understanding of the market

  • Data Accuracy & Reliability

    Strictly follows the Research Meth-odology for flawless results

  • Competitive Pricing

    Ensure the best and affordable pricing

  • Security & Confidentiality

    All your transactions are secured end-to-end, ensuring a satisfactory purchase